Company Profiles

driven by the PitchBook Platform

Acer Therapeutics

Description

Developer of pharmaceutical therapeutics for specialty orphan diseases designed to deliver life-changing benefits to patients who lack treatment options. The company's pharmaceutical therapeutics focuses on developing a strategy to repurpose and reformulate existing drugs and consists of two late-stage clinical products: ACER-002 for vascular Ehlers-Danlos Syndrome (vEDS), and ACER-001 for Maple Syrup Urine Disease (MSUD), enabling healthcare companise to treat orphan diseases with a significant unmet medical need.

2007

Founded

PRIVATE

Status

1-10

Employees

Later Stage VC

Latest Deal Type

$3.12M

Latest Deal Amount

$13.4M

Total Amount Raised

Description

Developer of pharmaceutical therapeutics for specialty orphan diseases designed to deliver life-changing benefits to patients who lack treatment options. The company's pharmaceutical therapeutics focuses on developing a strategy to repurpose and reformulate existing drugs and consists of two late-stage clinical products: ACER-002 for vascular Ehlers-Danlos Syndrome (vEDS), and ACER-001 for Maple Syrup Urine Disease (MSUD), enabling healthcare companise to treat orphan diseases with a significant unmet medical need.

Website:

www.acertx.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Pharmaceuticals

Other Industries

Drug Discovery
Biotechnology

Primary Office

222 Third Street Suite 2240 Cambridge, MA 02142United States
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Acer Therapeutics's full profile, request a free trial.

Acer Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Acer Therapeutics Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Acer Therapeutics Investors (1)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
TVM Capital Life ScienceVenture CapitalMinority000 0000000 0000
TVM Capital Life Science Venture Capital

Acer Therapeutics Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Christopher SchellingCo-Founder, Chief Executive Officer, President & Board Member
Benjamin DeweesVice President, Regulatory Affairs and Manufacturing
Robert Steiner MDChief Medical Officer
Harry PalminActing Chief Financial Officer
Jefferson DavisActing Chief Business Officer
Christopher Schelling Co-Founder, Chief Executive Officer, President & Board Member
Benjamin Dewees Vice President, Regulatory Affairs and Manufacturing
Robert Steiner MD Chief Medical Officer
Harry Palmin Acting Chief Financial Officer
Jefferson Davis Acting Chief Business Officer

Acer Therapeutics Board Members (5)

NameRepresentingRoleSinceContact
Info
Christopher SchellingAcer TherapeuticsCo-Founder, Chief Executive Officer, President & Board Member000 0000
Cynthia LavoieAcer TherapeuticsBoard Member000 0000
John Dunn JDAcer TherapeuticsDirector000 0000
Luc Marengere Ph.DTVM CapitalManaging Partner000 0000
Stephen AselageSelfChairman000 0000
Christopher Schelling Co-Founder, Chief Executive Officer, President & Board Member Acer Therapeutics
Cynthia Lavoie Board Member Acer Therapeutics
John Dunn JD Director Acer Therapeutics
Luc Marengere Ph.D Managing Partner TVM Capital
Stephen Aselage Chairman Self
Request full access to PitchBook